Abstract Adenosine is known to exert most of its physiological functions by acting as local modulator at four receptor subtypes named A 1 , A 2A , A 2B and A 3 (ARs). Principally as a result of the difficulty in identifying potent and selective agonists, the A 2B AR is the least extensively characterised of the adenosine receptors family. Despite these limitations, growing understanding of the physiological meaning of this target indicates promising therapeutic perspectives for specific ligands. As A 2B AR signalling seems to be associated with pre/postconditioning cardioprotective and anti-inflammatory mechanisms, selective agonists may represent a new therapeutic group for patients suffering from coronary artery disease. Herein we present an overview of the recent advancements in identifying potent and selective A 2B AR agonists reported in scientific and patent literature. These compounds can be classified into adenosine-like and nonadenosine ligands. Nucleosidebased agonists are the result of modifying adenosine by substitution at the N 6 -, C 2 -positions of the purine heterocycle and/or at the 5′-position of the ribose moiety or combinations of these substitutions. Compounds 1-deoxy-
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Introduction
Adenosine is involved in important biochemical processes, such as energy transfer [adenosine triphosphate (ATP) and adenosine diphosphate (ADP)] and signal transduction [cyclic adenosine monophosphate (cAMP)] and it is a building block for some biologically significant molecules such as nicotinamide-adenine-dinucleotide (NAD), flavinadenine-dinucleotide (FAD), S-adenosyl-L-methionine (SAM), DNA and RNA. The endogenous purine nucleoside (Ado, 1, Fig. 1 ) is ubiquitous in mammalian cell types and, in view of its function in regulating a wide number of physiopathological events (such as cytoprotective, antiinflammatory, central nervous system neurotransmitters regulator, pain transmission and metabolism modulator agent [1] [2] [3] [4] [5] [6] [7] [8] [9] ), there is wide-spread interest throughout the scientific community in the understanding of its molecular pharmacology and physiology. Adenosine and ATP have been shown to induce signalling via P1 and P2 receptors, respectively. P1 [adenosine receptors (ARs)] receptors are divided into four subtypes, all belonging to the family of cell-membrane Gprotein-coupled adenosine receptors named A 1 , A 2A , A 2B and A 3 , which have been cloned from many mammalian and some nonmammalian species [10] [11] [12] [13] .
A 2B ARs have been generally defined as the "lowaffinity ARs," as their lower affinity for the endogenous ligand, adenosine, and for some typical agonists, such as 5′-N-ethylcarboxamidoadenosine (NECA, 2, Fig. 1 ), N 6 -(R)-phenylisopropyladenosine (R-PIA), and 2-([4-(2-carboxyethyl)phenylethyl]amino)-5′-N-ethylcarboxamidoadenosine (CGS21680), by contrast with other AR subtypes [14] [15] . Under physiological conditions, intracellular adenosine reaches a concentration of 100 nM and thus is able to interact only with the high-affinity A 1 and A 2A AR subtypes. In hypoxic, ischaemic or inflammatory conditions, the intracellular levels of adenosine can grow to very high micromolar concentrations and, thanks to specific transports across cell membranes, the endogenous nucleoside can activate the low-affinity A 2B and A 3 AR subtypes. Activation of A 2B AR implies stimulation of adenylate cyclase and activation of phospholipase C through the coupling to Gs and Gq/11 proteins, respectively. A 2B ARs have been found on practically every cell in most species, and their sequences are highly similar across species. The human (h) A 2B AR shares, for example, 86-87% amino acid sequence homology with the rat and mouse subtypes [14] . Determination of receptor-coding messenger RNA (mRNA) levels furnished important information about A 2B AR tissue distribution. High concentrations of A 2B ARs have been suggested in caecum, large intestine and urinary bladder, whereas a lower expression has been revealed in lung, blood vessels, eye, and mast cells. Adipose tissue, adrenal gland, brain, kidney, liver, ovary and pituitary gland are thought to have a very low concentration of A 2B AR [12] .
A 2B ARs are known as the most poorly characterised of the adenosine P1 receptors from a pharmacological point of view, as their general low affinity towards prototypic ligands exerting specific high affinity and potency in activating each of the remaining AR subtypes. In particular, the scarcity of medicinal chemistry knowledge about the structural requirements necessary for potent and selective activation of the A 2B AR subtype has created wide-ranging difficulty in detecting the physiological effects mediated by direct and selective A 2B AR stimulation. Despite these limitations, growing and promising information in understanding the physiological meaning of these receptors has arisen from the exploitation of potency and selectivity of ligands for A 1 , A 2A and/or A 3 ARs by employing a strategy of exclusion in a model in which more AR subtypes are coexpressed. The A 2A AR-selective agonist CGS21680 has been reported, for example, as a useful tool for differentiation between A 2A and A 2B ARs [14] . Moreover, some potent and selective antagonists of the A 2B AR have been employed to distinguish A 2B AR-mediated effects. Until a few years ago, the characterisation of A 2B ARs through radioligand binding studies using low-affinity and nonselective antagonists such as [ [16] . A helpful advancement in the pharmacological characterisation of A 2B ARs is supposed to be increased by the recent identification of the tritiated form of some new A 2B AR antagonists with improved potency and selectivity, such as [ [18] and [ [19] .
The contribution of genetic engineering and manipulation (for example, generation of A 2B AR knockout mice and transgenic mice overexpressing this receptor), especially if combined with classic pharmacological investigations, have determined relevant progress in establishing the therapeutic potential of A 2B AR ligands and, generally, the role of ARs, in a variety of diseases [20] [21] [22] [23] .
A 2B adenosine receptor physiology and pharmacology
The A 2B AR subtype has been recognised to regulate a wide range of physiopathological events. However, it is mainly involved in modulating cardiovascular functions and the genesis of inflammation processes. A role for A 2B AR in regulating vascular tone, cardiac myocyte contractility, neurosecretion and neurotransmission, cell growth, gene expression, intestinal tone and secretion and mast-cell function has been suggested [14] . A 2B AR activation is -substituted-adenosine (3, 4) and NECA (5, 6) derivatives as nonselective A 2B AR agonists known to induce angiogenesis [24] [25] , reduce vascular permeabilisation [26] , increase release of inflammatory mediators from human and canine mast cells [24] and modulate neurohypophysial hormone output [27] . Adenosine, through A 2B ARs, can exert long-term control over glycogen levels in primary cultures of mouse cortical astrocytes and might therefore play a significant role in pathophysiological processes involving long-term modulation of brain-energy metabolism [21] . There is evidence of a probable involvement of A 2B ARs in the growth and development of some tumours , and A 2B ARs have been proposed as targets to control cell growth and proliferation in a human breast cancer cell line [28] .
ARs play a significant role in regulating ion transport in epithelial tissues through a variety of intracellular signalling pathways. Each of the four P1 receptors has distinctive roles in different epithelial tissue types. The A 2B AR has been identified on both the mucosal and basolateral aspect of colonic epithelial cells. Activation at either site results in Cl-secretion via direct activation of the cAMP-activated Cl − channel cystic fibrosis transmembrane conductance regulator (CFTR) [29] . An analogous process of adenosinemediated activation of Cl-secretion has been located at the lung epithelium [30] . The stimulated secretory response has been identified to be the result of A 2B AR activation and was lost in a cell line derived from a cystic fibrosis patient with a defect in ion transport at CFTR, implicating this ion channel as the one responsible for the A 2B AR-mediated Clsecretion [31] .
Therapeutic potential of A 2B adenosine receptor antagonists
There are growing findings supporting adenosine as having a role in asthma and chronic obstructive pulmonary disease (COPD) [32] . Moreover, adenosine stimulates production of interleukin (IL)-4 and IL-13 in mast cells via A 2B AR activation [33] . Treatment of asthma with selective A 2B AR antagonists has so far been one of the most significant therapeutic options among AR ligands [34] [35] [36] [37] [38] . A 2B AR antagonists are directed towards clinical use for treating diabetes, as these seem to antagonise the adenosineinduced hepatic glucose production determining reduction of blood glucose levels after oral administration [39] . A 2B AR has been likewise reported to be involved in stimulating proliferation, differentiation and migration of retinal endothelial cells. Thus A 2B AR antagonists may offer a way to inhibit retinal angiogenesis, providing a novel therapeutic approach for treating diseases associated with aberrant neovascularisation, such as diabetic retinopathy [40] .
The opioid and adenosine systems seem to cooperate to some extent in modulating pain signalling. In particular, participation of A 2B ARs in the analgaesic effects mediated by caffeine in an acute animal model of nociception (hotplate test) has been documented [41] . These findings support the potential therapeutic employment of specific A 2B AR antagonists as valuable adjuvant drugs for opioid analgaesia, with minimal side effects.
The purinergic regulation of epithelial transports and, above all, involvement of the A 2B AR subtype in determining secretion stimulation, suggest the possibility of employing A 2B AR-specific ligands as potential modulators of ion transport and the parallel flux of water, which can be considered a natural defence system working to "wash away" injuries in the setting of cellular damage or inflammation. Selective A 2B AR ligands are under investigation for treating diarrhoea and cystic fibrosis [42] [43] [44] .
Therapeutic potential of A 2B adenosine receptor agonists
Ischaemic preconditioning (IPC) is a cardioprotective mechanism according to which brief and repeated episodes of sublethal ischaemia and reperfusion, before myocardial infarction, cause the heart to become resistant to infarction and result in attenuation of infarct size. Activation of cardiac A 2B AR receptors at reperfusion showed to be protective in the rabbit, but because of the very low affinity of the receptors, endogenous cardiac adenosine is unable to elicit their signalling. Protein kinase C physiologically increases the heart's sensitivity to adenosine so that endogenous adenosine can activate A 2B AR-dependent signalling. 2-[6-amino-3,5-dicyano-4-(4-hydroxyphenyl) pyridin-2-ylsulfanyl]acetamide (BAY 60-6583), a highly selective A 2B AR agonist [45] (Fig. 3) , resulted in limited infarct size when given to rabbit-ischaemic hearts at reperfusion [46] . Postconditioning protects the heart with multiple brief reperfusion/ischaemia cycles immediately following the ischaemic insult. In rabbit hearts, binding of endogenous adenosine to A 2B ARs in early reperfusion is a requirement for both IPC and postconditioning to limit infarction [47] .
A pharmacological and gene-targeting approach performed with mice models to study the contributions of AR signalling to ischaemic preconditioning cardioprotection provided evidence that selective A 2B AR agonists may offer important advantages in comparison with classical therapies of acute myocardial ischaemia [48] . Intravenous administration of nonselective adenosine is associated with side effects (bradycardia, hypotension, rapid receptor desensitisation), which could be circumvented by the use of specific A 2B AR agonists [23] .
Deletion of the gene encoding the A 2B AR in the mouse (A 2B AR-knockout mouse model) recently resulted in increased production of proinflammatory cytokines, altered response to endotoxin exposure, increased leukocyte adhesion and increased leukocyte rolling on blood vessels [49] . Activation of A 2B AR subtype would moreover increase production of the anti-inflammatory cytokine IL-10 [50] .
The described association of A 2B AR with pre/postconditioning cardioprotection, along with the documented strong anti-inflammatory role of A 2B AR signalling [49] , suggests that A 2B AR agonists may represent a new group of therapeutics for patients suffering from coronary artery disease. Several reports contribute to strengthen this perspective, highlighting essential A 2B AR-mediated cardiovascular effects. A NECA-mediated coronary vasodilation via the A 2B AR subtype in isolated hearts from young (1-2 months) and mature (12-18 months) Wistar rats has been documented [51] . Adenosine-mediated vasorelaxation in mouse aorta is partially dependent on A 2B AR [52] , and A 2B ARs mediate relaxation in human small resistance-like coronary arteries, which is independent of nitric oxide (NO) but partly coupled to potassium (K + ) channel function [53] . Human aortic smooth muscle cells (SMCs) synthesise adenosine, which seems to protect against vasoocclusive disorders by inhibiting SMC proliferation and collagen synthesis via activation of A 2B AR receptors [54] . Apoptosis of arterial smooth muscle cells (ASMCs) could play an important role in the pathogenesis of atherosclerosis and restenosis. Recent results indicate that adenosine-induced apoptosis of cultured human ASMCs is essentially mediated via A 2B AR and involves a cAMP-dependent pathway [55] . These studies speculated that adenosine could play a dual role in the evolution of intimal thickening. Its action can be considered beneficial concerning control of intimal hyperplasia and thickening formation. In contrast, the same authors indicated that adenosine could contribute to the formation of the necrotic core in advanced atherosclerotic lesions, promoting-along with other concurrent factors-plaque rupture. These opposing effects suggest different therapeutic strategies based on the role of A 2B AR stimulation-mediated effects in the pathogenesis of atherosclerosis and restenosis.
Glomerular mesangial cell (GMC) growth is inhibited by A 2B AR activation coupled with inhibition of mitogenactivated protein kinase (MAPK) activity [56] . A 2B AR function may therefore largely affect glomerular remodeling associated with GMC proliferation. Identification of pharmacological agents able to specifically activate A 2B ARs has been purported to be of therapeutic importance in protecting against glomerular remodeling associated with glomerulosclerosis, renal disease and abnormal GMC growth associated with hypertension and diabetes.
Studies performed by the Shiseido Research Group indicate that adenosine, via A 2B AR, might stimulate hair growth through fibroblast growth factor-7 gene expression upregulation in dermal papilla cells [57] .
In the research field concerning vasculogenic erectile dysfunctions, there emerged key importance regarding purinergic transmission for initiating and maintaining penile erection [58] . Endothelial dysfunction of human corpus cavernosum may be correlated with the loss of adenosine A 2B ARs activity, indicating a possible employment of specific A 2B AR agonists as anew therapeutic approach to manage severe vasculogenic impotence resistant to common vasodilators [59] .
As interaction of adenosine with A 2B ARs inhibits production of the proinflammatory cytokine tumor necrosis factor (TNFα) by lipopolysaccharide-activated monocytes [49, 60] , A 2B AR agonists have been proposed for treating septic shock, confirming the broad anti-inflammatory potential of AR agonists in treating inflammatory disorders [61] .
A 2B adenosine receptor agonists
The lack of molecules endowed with selective and potent agonistic activity towards the hA 2B ARs has limited the studies on this pharmacological target and consequently the evaluation of its therapeutic potential. Several ligands for A 2B AR have been identified in recent years [62] [63] [64] . However, only very recently have some reports about important advancement in identifying A 2B AR agonists with improved in vitro pharmacological profile been published.
Medicinal chemistry literature concerning the field of AR agonists is generally characterised by the absence of binding data related to the A 2B AR subtype, caused by the substantial lack of a useful radiolabelled agonist. Therefore, for the time being, the selectivity profile of new potential A 2B AR agonists can only be speculated in view of the ratio of binding parameters (K i values for A 1 , A 2A , A 3 ARs) to functional parameters (EC 50 for A 2B , Tables 1, 2 , 3, 4, 5, and 6).
The compounds of particular interest for the development of potent and selective A 2B AR agonists can be classified into adenosine-like and nonadenosine-like ligands. Nucleoside-based agonists are the result of modifying the endogenous ligand, adenosine, by substitution at the N 6 -, C 2 -positions of the purine heterocycle and/or at the 5′-position of the ribose moiety. In particular, the most potent and subtype-selective ligands have been obtained by combining these substitutions (i.e., multiply substituted adenosines). This group can be subdivided into the following subclasses: N 
Adenosine-like ligands
In the search for A 2B AR agonists, de Zwart et al. reported a functional screening, based on adenylate cyclase stimulation, of known adenosine analogues variously modified at the 2-, 5-, 8-, N 6 and 5′ positions (or combinations of these) [65] . This study indicated NECA (5′-N-carboxamidoadenosine, 2, Fig. 1 ) as the most potent ligand since then reported. More generally, after these first studies, the 5′-Ncarboxamidoadenosines seemed more potent than the corresponding 4′-CH 2 OH derivatives, N 6 -substitution showed higher compatibility with A 2B AR subtype compared with C 2 -and/or C 8 -substitutions and deazapurine derivatives resulted as inactive. Thus, N 6 -substituted-5′-Ncarboxamidoadenosine derivatives were initially considered as the most promising tool for identifying A 2B AR agonists. More recently, a series of carboxamido and thiocarboxamidoadenosines bearing several 5′-N-(cyclo)alkyl groups [66] have been synthesised and tested at the four AR subtypes. The replacement of the 5′-N-ethyl carboxamido function of NECA with other alkyl groups or the thiocarboxamido moiety led to a significant loss of A 2B AR potency and, in some examples, to reduced intrinsic activity (data not shown).
Some examples of N 6 -substituted adenosine derivatives endowed with satisfactory levels of A 2B AR potency have been reported [62] . In particular, the introduction of (substituted) phenyl rings at the N 6 -position led to the identification of compounds such as the 4-I-phenyl and 4-aminosulfonylphenyl derivatives 3 and 4 ( Fig. 1 ) displaying submicromolar potency in activating the A 2B AR subtype [64] . -(hetero)aryl-carbamoyl-methoxy-phenyl)-(2-chloro)-NECA derivatives 7-18 at the human adenosine receptors expressed in CHO cells [69] groups yielded compounds endowed with similar activity as the corresponding adenosine analogues (N 6 -(4-chlorophenyl) NECA, 5, EC 50 =0.73 μM) [67] . In a recent study of modelling and site-directed mutagenesis performed with the aim of defining the leading parameters affecting the interaction between A 2A AR and its specific agonists [68] , the N 6 -guanidino derivative 6 of NECA ( Fig. 1 ) was identified. Replacement of the 6-amino group of NECA with the guanidino moiety determined a threefold enhancement in A 2B AR activation potency (EC 50 =54.5 nM versus 140 nM of NECA) and an increased selectivity versus A 2A AR subtype (K i =628 nM versus 2.2 nM), maintaining a high affinity at the A 3 (K i =5.1 nM) and A 1 ARs (K i =7.0 nM).
The disubstitution of the amino group at the 6-position of adenosine is not tolerated by A 2B AR subtype (data not shown) [64] .
A novel series of potent but low-selective A 2B AR agonists structurally related to NECA has been recently reported by Baraldi et al. [69] . These compounds were designed modifying the N 6 -position of 5′-N-carboxamidoadenosine in analogy with the typical substitution pattern of some potent and selective A 2B AR antagonists previously reported in the literature. Several A 2B AR antagonists with high affinity and good selectivity have, in fact, been identified among structures based upon a xanthine core suitably substituted at the 1-, 3-and 8-positions [70] . In particular, Kim et al. [71] reported that a (substituted) phenylcarbamoyl-methoxy-phenyl chain at the 8-position of a series of 1,3-dipropyl-xanthines was able to specifically direct the antagonist activity to the A 2B AR. Further evidence of the important role of the substituent at the 8-position as the structural selectivity element for the design of potent A 2B AR antagonists was provided recently by our group [72] .
Considering the previous structure activity relationship (SAR) studies, regarding NECA and adenosine derivatives indicating the N 6 as a useful position for A 2B AR bindingsite recognition, a new series of N 6 -[(substituted)phenyl/ cycloalkyl/benzyl/heteroaryl-carbamoyl-methoxy-phenyl]-5′-N ethylcarboxamido-adenosine and 2-chloro-adenosine derivatives (7-18, Table 1 ) has been designed and synthesised. These molecules can be considered as molecular hybrids obtained by the introduction of an arylcarbamoyl-methoxy-phenyl chain (supposed to grant A 2B AR selectivity as in the cited series of xanthine derivatives) at the N 6 -position of the typical nucleoside nucleus responsible for AR activation. The key role of this position in the formation of the A 2B AR-ligand complex has been confirmed by a molecular modelling investigation performed with the human A 2B AR. The docking of known A 2B AR agonists highlighted, in fact, involvement of the exocyclic amino group at the 6-position of NECA in an important interaction with a residue of asparagine 254 belonging to the VI transmembrane receptor helix [73] . The 2-chloro atom was introduced, as the literature in the field of A 2B AR agonists indicates the 2-position as a second possible site of modification of the purine nucleus [74] .
As described in Table 1 ARs. The compounds were also evaluated in a functional assay, measuring their capacity to modulate cAMP levels in CHO cells expressing hA 2B [75] . A lower, but significant, affinity for the A 3 AR was observed. The most selective compounds versus A 3 AR subtype were the unsubstituted phenyl derivative (7) and the 4-halo-phenyl derivatives (8) (9) (10) (11) . The cAMP functional assay tested that the designed molecules behave as full A 2B AR agonists. These compounds represent, to the best of our knowledge, the first report about adenosine-related structures capable of activating hA 2B AR subtype in the very low nanomolar range.
In the search for nucleoside-based ligands for ARs, some N 6 -carboxamido derivatives of adenosine-5′-Nethyluronamide (NECA) have been synthesised and tested in binding and/or functional assays at the four known AR subtypes exerting a general behaviour as low-selective A 1 AR ligands [76] . Some N 6 -(substituted-phenylcarbamoyl)-derivatives of NECA were instead found to have affinity at rat A 3 ARs in the low nanomolar range, with different degrees of selectivity versus A 1 and A 2A ARs [77, 78] . These results indicated that small modifications of the chain at the 6-position of the purine nucleus can produce significant changes in the selectivity pattern of potential AR ligands. According to the principles of bioisosterism, the (hetero)aryl-urea function of the reported A 3 AR agonists has been recently replaced with the isomeric (hetero)aryl-carbonyl-hydrazino moiety, and the effect on binding and functional profile of the synthesised compounds has been evaluated [79, 80] . The coexisting effect of substitution at the 2-position of the purine with a chlorine atom has also been examined. 125 I]-AB-MECA, respectively. The compounds were also evaluated in functional assays, measuring their capacity to modulate cAMP levels in CHO cells expressing hA 2B ARs. Structures and biological data of a selection of the synthesised compounds are listed in Table 2 .
The series has been developed introducing different (substituted) heteroaryl nuclei on the N The most innovative finding rests in the analysis of the selectivity information emerging from the comparison between affinity and functional data related to the four AR subtypes. Of the examined molecules, the ones showing the capability to activate A 2B ARs were inactive at the hA 3 AR (K i >5,000 nM) and showed high nanomolarmicromolar affinity at the A 1 and A 2A AR subtypes (K i varying from 700 to 5,000 nM). In particular, compound 1-deoxy-1-{6-[N′-(furan-2-carbonyl)-hydrazino]-9H-purin-9-yl}-N-ethyl-β-D-ribofuranuronamide (19, hA 1 ,hA 2A K i > 1,000 nM; hA 2B EC 50 =82 nM, hA 3 K i >5,000 nM) was the most potent of the series, and it was confirmed to be a full [45, 46] >10,000 >10,000 3 nM >10,000
agonist in a functional assay based on the measurement of its capacity to modulate cAMP levels in CHO cells expressing hA 2B AR (Fig. 2) . Nevertheless, both furan and thiophene rings were shown to exert similar favourable interactions for receptor activation [compare furan derivatives, 21 (hA 2B EC 50 =227 nM) and 23, with the related thiophene derivatives 22 (hA 2B EC 50 =273 nM) and 26]. The presence of the chlorine atom at the 2-position of the purine nucleus did not seem to affect the ability of the tested compounds to activate hA 2B AR, as is clear from the comparison of chlorinated derivatives 23 (hA 2B EC 50 =210 nM) and 24 (hA 2B EC 50 = 175 nM) with the corresponding nonchlorinated 19 (hA 2B EC 50 =82 nM) and 22 (hA 2B EC 50 =273 nM). The examined molecules can be considered valuable tools for the design and development of new and even more selective and potent ligands.
The introduction of a bulky substituent at the 2-position of the adenine ring of NECA is known to induce A 2A AR-selective agonistic activity. CGS21680 has, in fact, been considered one of the most potent A 2A AR agonist and the ligand of choice to distinguish A 2A -and A 2B AR-mediated effects (K i values from binding assays for hA 1 , hA 2A and hA 3 AR subtypes of 298, 27 and 67 nM respectively; EC 50 value from stimulation of adenylyl cyclase activity through A 2B AR of 88.8 μM) [11] . The first attempts to substitute the 2-position of adenosine indicated that A 2B AR did not tolerate well such structural modulation [65] . An appreciable improvement of A 2B AR affinity has, however, bgeem recognised, introducing a 2-chloro atom (2-ClAdo, 27, Table 3 , EC 50 from measurement of receptor-stimulated adenylate cyclase activity in CHO, stably transfected with hA 2B AR of 24 μM) or 2-alkynyl chains. The racemic 2-
had been found to exert activity at A 2B AR comparable with that of NECA (EC 50 =2.4 μM). The (R) diastereomer of PHPAdo (LUF 5599, 29, EC 50 =6.2 μM) was almost sevenfold less potent than the (S) optical isomer (LUF 5600, 30, EC 50 =0.92 μM). The introduction of small alkyl chains at the N 6 position of (R,S)-PHPAdo was shown to be tolerated for interaction with A 2B AR, whereas large groups abolished A 2B AR potency (data not shown) [81] . In particular, for N 6 -ethyl-(R,S)-PHPAdo (31), an EC 50 from adenylyl cyclase assay of 1.7 μM has been reported [82] . Substitution of the 2-position of NECA with alkynyl chains results in an increase of A 2B AR affinity, as demonstrated by the compound named 2-phenylhydroxypropynyl-5′-N-ethylcarboxamidoadenosine (PHPNECA, 32) displaying agonistic activity in a functional assay at this AR subtype, with an EC 50 value of 1.1 μM [83] . The racemic (R,S)-PHPNECA resulted in a twofold greater potency than the optically pure (R)-PHPNECA (33, hA 2B EC 50 =2.4 μM) and a five fold smaller potency than the (S) diastereomer (34, hA 2B EC 50 effect on binding, as demonstrated by derivative (R,S)-2-(3-hydroxy-1-pentynyl) NECA 36, which was as potent as (R, S)-PHPNECA in activating A 2B AR subtype (hA 2B EC 50 = 1.3 μM). The presence of a hydroxyl group in α to the triple bond appeared to be important for activity. The (R,S)-2-(4-hydroxy-1-pentynyl) NECA 37, bearing a hydroxyl group in β to the triple bond, was, in fact, 12-fold less potent than (R, S)-PHPNECA (hA 2B EC 50 =13.3 μM) [62] . The 5′-methylcarboxamido analogue of (R,S)-PHPNECA ((R,S)-PHPMECA, 38) was 4.5-fold less active than the parent compound (hA 2B EC 50 =5.0 μM) [74] . A computational molecular docking of an heterogeneous set of 46 known adenosine-like AR agonists, based on the molecular models of the 3D structure of the four known AR subtypes, was recently performed [84] . Comparison between the putative ligand-receptor complexes for each receptor subtype suggested a general agonist-binding mode, along with possible explanations for the differences in agonist activities and AR selectivities. Some interesting estimations about the binding mode of agonists at the A 2B AR subtype have been highlighted, with particular attention to PHPNECA and its 2-hydroxypropynyl-substituted congeners. Specifically, the supposed orientations of ligands inside the AR binding sites suggested that, in general, the A 2A and A 2B AR subtypes have a smaller volume of the putative hydrophobic pocket surrounding the 5′-N-alkyl substituent than the A 1 and A 3 ARs. That gave a possible explanation for the decreased affinity characterising carboxamido derivatives in which sterically demanding alkyl groups were introduced at the 5′-N-position. Comparative analysis of the different binding modes of optical isomers of the 2-hydroxypropynyl-substituted agonists led to suppose a critical involvement of the orientation of the hydroxyl group, which resulted in affecting the capability to establish key Hbond interactions with the binding site. Specifically, the proposed binding mode of PHPNECA gave a rational explanation for the higher affinity of the (S)-PHPNECA in comparison with its (R) diastereomer, demonstrating that the hydroxyl group of the (S)-phenylhydroxypropynyl fragment could be hydrogen bonded to a cysteine residue located in the second extracellular loop. On the contrary, the hydroxyl group of the (R)-phenylhydroxypropynyl chain seems to be surrounded by hydrophobic residues of Leu and Ala, thus resulting in unfavourable ligand-receptor interactions.
In a recent study by Jacobson et al. [85] , a wide series of 2-substituted adenosine derivatives was evaluated for their affinity and efficacy through radioligand binding and cAMP functional assays in intact CHO cells at the four AR subtypes. This study included different 2-(cyclo)alkoxy, 2-(substituted/hetero)arylalkyloxy, 2-phenethylamino and 2-phenethylsulfanyl substitutions of adenosine. Most of these compounds were found to be extremely weak at the A 2B AR; nevertheless, 2-(phenylethyloxy)adenosine 39 ( Based on the findings that among these molecules, specific 2-(2-aryethyloxy)ether derivatives also displayed significant activity at the A 2B AR subtype and that 2-ethers were more potent than the corresponding amines or thioethers, the same authors subsequently reported on a structure-activity relationship study of 2,N 6 ,5′-substituted adenosine derivatives, which led to the identification of compounds with enhanced potency at the A 2B AR and reduced potency at the other AR subtypes [86] . In particular, 2-(3-indolyl)ethyloxy) adenosines substituted at the 5″ or 6″ positions of the 2-indole moiety with halogens or a hydroxyl function exerted micromolar potency in activating A 2B AR (EC 50 values from cAMP functional assay ranging from 0.128 to 1 μM), with slightly improved selectivity versus the other AR subtypes in comparison with previously reported reference compounds [NECA, (S)-PHPNECA and 6-guanidino-NECA]. Structures and corresponding potency/affinity data of a selected series of these compounds at the four known AR subtypes are reported in Table 4 . Compound 2-(3″-indolylethyloxy)adenosine 42 was found to be a rather potent agonist at the hA 2B AR (EC 50 =299 nM), although the selectivity profile was not so satisfactory (K i values at A 1 , A 2A , A 3 ARs of 148, 45, 232 nM, respectively). Substitution of the indole moiety with other (hetero)aryl nuclei, such as phenyl, naphthyl, thiophene, pyrrole, benzoimidazole or benzotriazole, did not succeed in enhancing A 2B AR potency. Elongation or branching of the 2-alkyl spacer proved to weaken the affinity against all ARs. 2-Indolyl derivative decreased markedly A 2B AR potency compared with 3-indolyl analogues, revealing that altered connectivity failed to improve the binding profile of the series (data not shown). The 5′-N-ethyluronamido analogue of 42 was synthesised, considering that replacement of the 4′-hydroxymethyl group with a 5′-N-ethylcarboxamido function is generally known to favour A 2B AR interaction. Unexpectedly, in the 2-(3-indolyl)ethyloxyadenosine series, this structural modification generated a threefold loss of potency (EC 50 hA 2B =989 nM), hypothetically due to an unfavourable change in the conformation of the ribose ring in the ligand-binding site. Similar results were achieved introducing at the N 6 -position of 42 an ethyl group (EC 50 hA 2B = 3,270 nM). Considering the potency of compound 42, the authors replaced its 6-amino group with a N 6 -guanidino moiety detecting decreased potency at the A 2B AR (hA 2B = 40% of activation at 10 μM), along with reduced selectivity versus A 1 (K i hA 1 =73.6 nM) and A 3 (K i hA 3 =90 nM) AR subtypes. The best results in terms of A 2B AR potency and selectivity were achieved by substitution of the indole nucleus of compound 42 with halogens (compounds 43-46, Table 4 ).
In particular, the 6-bromo derivative 45 exerted higher potency (EC 50 3 ARs and as full agonist at A 2A and A 2B AR subtypes (data not shown). A molecular modeling investigation performed by docking compound 2-(3″-(6″-bromo-indolyl)ethyloxy)adenosine 45 in the rhodopsin-based molecular model of the human A 2B AR gave rational explanations for the experimental pharmacological results, indicating that all the interactions previously proposed for adenosine could be strengthen by favourable interactions of the 2-(6-bromoindol-3-yl)ethyloxy chain with a distal region of agonist-receptor-binding site. Moreover, the 2-oxygen atom seemed to be involved in H bonding, with a residue of Asn, whereas the NH of the indole ring seemed in proximity of the OH of a residue of Ser, with which a hydrogen bond, even not fully detected, cannot be excluded.
Nonadenosine agonists
Based on some patent claims concerning the synthesis of a series of substituted 2-amino-4-phenyl-6-phenylsulfanylpyridine-3,5-dicarbonitriles as agonists for ARs [45, 87] , IJzerman et al. reported a series of five 2-amino-6-(1H-imidazol-2-ylmethylsulfanyl)-4-(substituted)phenyl pyridine-3,5-dicarbonitrile derivatives displaying high-potency agonistic activity for the hA 2B AR with somewhat significant selectivity versus the hA 3 AR subtype [88] . The ability of such compounds to activate the human A 2B AR has been determined through cAMP assay in CHO cells stably expressing this receptor. For comparison, affinity for the hA 1 (Table 5 ). All the reported compounds interacted with the hA 2B AR, with EC 50 ranging from 9 to 34 nM. Percentages of efficacy in modulation (inhibition for A 1 and A 3 , stimulation for A 2A and A 2B ARs) of the cAMP production functional assay reported in Table 5 (LUF5845) behaved as a potent (EC 50 =9 nM) partial agonist (efficacy of 33% compared with NECA) of the hA 2B AR. The authors proved that the effect on cAMP production was mediated by interaction of the reported compounds with the hA 2B AR, establishing that the potent AR antagonist CGS15943 was able to cause a dose-dependent decrease of the cAMP production induced by NECA and by the examined structures. The 4-p-OH-phenyl derivative (49, LUF5834) is of particular interest, thanks to its high potency at the hA 2B AR (EC 50 =12 nM) associated with a significant selectivity versus the hA 3 AR subtype (K i =538 nM, efficacy 74%). This ligand can be considered a useful tool for distinguishing the relative contributions of the A 2B and A 3 ARs to mast-cell-mediated activation of angiogenesis, a process that seems to be regulated by a combined action of A 2B and A 3 AR subtypes [88] . Table 6 ) as dual A 1 /A 2B AR agonists for treating diseases such as dyslipidemia, metabolic syndrome and diabetes, metabolic syndrome and diabetes in connection with hypertonia and diseases of the cardiovascular system. Moreover, new experimental evidence points to compound 53 as the representative dual A 1 / A 2B AR agonist (EC 50 values of 0.2, 0.1 and 236 nM for A 1 , A 2B and A 2A hAR subtypes, respectively), also potentially useful for treating and/or preventing hypertension, hypertonya, restenosis and thrombosis [90] .
Compounds 2-[6-amino-3,5-dicyano-4-(4-hydroxyphenyl) pyridin-2-ylsulfanyl]acetamide (57) and 2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-ylsulfanyl]acetamide (BAY-60-6583, 58) have been examined as A 2B AR agonists for their potential in treating disorders of the coronary arteries and atherosclerosis [45] , as well in the production of pharmaceuticals for prophylaxis and/or treatment of ischaemia-reperfusion injury [91] . Other possible clinical developments seem related to limitation of reperfusion cellular damage in mammals, especially in humans, following, for example, myocardial infarction, coronary artery bypass grafting and open heart surgery. In particular, compound BAY-60-6583 is under preclinicalphase investigation for treating angina pectoris. BAY-60-6583, characterised with CHO cells expressing recombinant human A 1 , A 2A or A 2B ARs, showed EC 50 values for receptor activation >10,000 nM for both A 1 and A 2A AR and 3 nM for A 2B AR subtypes. Moreover, it showed no agonistic activity in the adenosine A 3 -Gα16 assay up to a concentration of 10 μM [46] . In a rabbit model of myocardial ischaemic injury, this compound (100 mcg/kg i.v.) reduced the infarction area when administered to ischaemic rabbit hearts just prior to reperfusion, thus mimicking the effects of postconditioning procedure, which consisted of four cycles of 30-s reperfusion/30-s occlusion following ischaemia. Furthermore, the addition of nonspecific and A 2B AR-selective antagonists (MRS 1754 [71] ) blocked protection from postconditioning. Together, these data demonstrate that protection from postconditioning involves A 2B ARs [92] .
The possible use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines (with particular attention to compound 59) for the production of a medicament for the prophylaxis and/or treatment of nausea and vomiting is under investigation [93] .
Conclusions
With this review, we provide an overview of the latest advancements in the research field concerning the identification of agonists for A 2B AR, with particular attention to the past 2 years. The lack of agonists endowed with satisfactory levels of A 2B AR potency and selectivity has hampered the pharmacological characterisation of this potential therapeutic target. Important progresses in the field has been newly attained, thanks to the identification of both nucleoside-like (1-deoxy-1-{6-[N′-(furan-2-carbonyl)-hydrazino]-9H-purin-9-yl}-N-ethyl-β-D-ribofuranuronamide, 19) and nonadenosine (BAY-60-6583) molecules with undoubtedly improved in vitro pharmacological profile. A schematic overview of the most effective substitutions of adenosine and nonadenosine derivatives is furnished in Fig. 4 . In particular, the gain in A 2B AR selectivity promoted in these new agonists would provide useful pharmacological probes for exploring the role of in vivo receptor activation, and thus a more complete insight of the prospective employment of A 2B AR ligands in clinical therapy might be offered.
